Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Innovative nebulizer to treat cystic fibrosis developed by Cambridge Consultants

Observing surfers with cystic fibrosis (CF) led scientists to discover that the inhaled mist of seawater has a therapeutic effect on the lung problems associated with the disease. Now the findings have been used by pharmaceutical company Parion Sciences and product development firm Cambridge Consultants in a revolutionary new aerosol delivery system. It enables CF sufferers to get the benefits of saltwater treatment in their own homes overnight while they sleep.

23 May 2013

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis.

21 May 2013

Great Strides: Walk for cystic fibrosis

Walks in nearly every state this weekend will raise funds to fight cystic fibrosis as part of Great Strides, the Cystic Fibrosis Foundation's largest national fundraising event.

18 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

American Association for Respiratory Care names Jefferson a Quality Respiratory Care Institution

Thomas Jefferson University Hospital was recently bestowed the title of "Quality Respiratory Care Institution" for 2013 by the American Association for Respiratory Care.

16 May 2013

Magic bullet nanomedicine offers potential treatment option for Acute Lung Injury

Researchers at Queen's University Belfast have devised a 'magic bullet' nanomedicine which could become the first effective treatment for Acute Lung Injury or ALI, a condition affecting 20 per cent of all patients in intensive care.

15 May 2013

Research could help battle stubborn bacterial infections that do not respond to antibiotics

Bacteria on a surface wander around and often organize into highly resilient communities known as biofilms. It turns out that they organize in a rich-get-richer pattern similar to many economies, according to a new study by researchers at UCLA, Northwestern University and the University of Washington.

10 May 2013

Researchers discover potential treatment for deadly, drug-resistant bacterial infections

Through the serendipity of science, researchers at the University of Pittsburgh have discovered a potential treatment for deadly, drug-resistant bacterial infections that uses the same approach that HIV uses to infect cells.

8 May 2013

Scientists uncover unknown virulence factor in respiratory pathogen

To infect its host, the respiratory pathogen Pseudomonas aeruginosa takes an ordinary protein usually involved in making other proteins and adds three small molecules to turn it into a key for gaining access to human cells.

7 May 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

Selenium research performed by Dr. Joel Wallach continues to be at the forefront of health and prevention

Youngevity® Essential Life Sciences, a wholly-owned subsidiary of AL International, Inc., announces that the research of Youngevity® founder, Dr. Joel D. Wallach, BS, DVM, ND, on Selenium continues to be at the forefront of health and prevention with the recent U.S. Food and Drug Administration (FDA) proposed rule requiring the addition of selenium to the list of required nutrients for infant formula products.

22 Apr 2013

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Vertex Pharmaceuticals Incorporated today announced data from a Phase 2 study of VX-661 and ivacaftor that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, known as F508del.

22 Apr 2013

Protein EPAC2 plays major role in development of type 2 diabetes

A team of researchers at the Johns Hopkins Children's Center has found that a protein long believed to have a minor role in type 2 diabetes is, in fact, a central player in the development of the condition that affects nearly 26 million people in the United States alone and counts as one of the leading causes of heart disease, stroke and kidney, eye and nerve damage.

12 Apr 2013

Physicians uncertain about hospitalization for PID treatment

A Johns Hopkins Children's Center survey of 102 clinicians who treat teenage girls with pelvic inflammatory disease has found that official guidelines designed to inform decisions about hospitalization versus outpatient care leave some clinicians scratching their heads.

10 Apr 2013

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream.

9 Apr 2013

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase.

2 Apr 2013

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic azithromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA.

27 Mar 2013

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic erythromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA.

27 Mar 2013

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.

24 Mar 2013

Translational Research's April issue examines progress, outlook of gene therapy research

The April issue of Translational Research examines the progress and outlook of gene therapy research, with a specific focus on the clinical applicability of gene therapy today.

22 Mar 2013

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Innovative nebulizer to treat cystic fibrosis developed by Cambridge Consultants

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Great Strides: Walk for cystic fibrosis

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

American Association for Respiratory Care names Jefferson a Quality Respiratory Care Institution

Magic bullet nanomedicine offers potential treatment option for Acute Lung Injury

Research could help battle stubborn bacterial infections that do not respond to antibiotics

Researchers discover potential treatment for deadly, drug-resistant bacterial infections

Scientists uncover unknown virulence factor in respiratory pathogen

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

Selenium research performed by Dr. Joel Wallach continues to be at the forefront of health and prevention

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Protein EPAC2 plays major role in development of type 2 diabetes

Physicians uncertain about hospitalization for PID treatment

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Erythromycin may provide benefit for patients with non-CF bronchiectasis

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

Translational Research's April issue examines progress, outlook of gene therapy research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in